Catherine Stehman - Breen
Director at Generation Bio
Catherine was appointed chief development officer of Obsidian Therapeutics in 2019. Previously, she was entrepreneur-in-residence at Atlas Ventures, serving as chief medical officer of both Dyne Therapeutics and Disarm Therapeutics. She also spent time as chief medical officer of Sarepta Therapeutics. Prior to that, Catherine served as vice president, clinical development and regulatory affairs at Regeneron Pharmaceuticals, initially as head, pain therapeutic area, and subsequently as head, clinical project management and operations. From 2003 to 2015, she held senior leadership roles at Amgen including vice president, global development, leading the neuroscience, nephrology and bone therapeutic areas. Dr. Stehman-Breen earned her M.D. from the University of Chicago in 1990. She conducted her residency and fellowship training at the University of Washington, where she also received a Master of Science degree in Epidemiology in 1996. Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington from 1997 to 2003, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in kidney disease patients. Dr. Stehman-Breen was also active in a variety of national programs including serving as the Chair for USRDS NIDDK External Expert Panel and a reviewer for several journals.
ColleaguesView in org chart
Board & Advisors
Robert KotinAdvisor & co-Founder